12,372 trials
Pneumococcal Infections
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1 — 146; 104; 200; 353 titer
Obesity
Primary: Percent Weight Loss From Baseline to Week 28 — 1.7; 5.5; 5.1; 8.5 percent weight loss — p=0.0009
Urinary Incontinence
Primary: Mean Residual Urine Volume — 12.4; 9.4 mL
Breast Cancer
Primary: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. — 6.93; 2.83 months — p=<0.0001
Obesity
Primary: Percent Weight Change at End of Treatment, Week 108. — -1.8; -9.32; -10.5 percent weight loss — p=<0.0001
Brain Edema · Brain Tumor
Primary: Long Term Safety and Tolerability of hCRF — 111 Participants
Rheumatoid Arthritis
Primary: Percentage of Patients Developing a Serious Adverse Event (SAE) Within 24 Weeks After Receiving the First Course of Rituximab Treatment — 6.0; 9.1 Percentage of…
Hereditary Angioedema · Angioneurotic Edema
Primary: Time to Beginning of Relief of Symptoms — 68; 122; 258; 62.5 minutes — p=0.001
Asthma
Primary: FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation — 617.56; 634.64 milliLiters x minutes
Schizophrenia · Bipolar Disorder
Primary: Percentage of Subjects Experiencing SAEs — 6.2 percentage of participants
Age Related Macular Degeneration
Primary: Change From Baseline in Visual-acuity Score (Continuous) — 8.5; 8.0; 6.8; 5.9 No. of Letters — p=0.16
Hereditary Angioedema · Angioneurotic Edema · Genetic Disorders
Primary: Time to Beginning of Relief of Symptoms — 62; 508; 61 minutes — p=0.003
Asthma
Primary: Adverse Events — 14; 24 adverse events
Type 1 Diabetes
Primary: The Area Under the Curve (AUC) of Plasma Glucose (PG) Concentrations During the 5-hour Postprandial Period (AUC-PG0-5 h). — 724.6; 668.8 mg*h/dl
Tuberous Sclerosis Complex (TSC) · Lymphangioleiomyomatosis (LAM)
Primary: Angiomyolipoma Response Rate as Per Central Radiology Review — 41.8; 0; 58.0 Percentage of Participants — p=<0.0001